Pure Global

A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes - Trial NCT06326047

Access comprehensive clinical trial information for NCT06326047 through Pure Global AI's free database. This Phase 2 trial is sponsored by Novo Nordisk A/S and is currently Recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 288 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06326047
Phase 2
Recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06326047
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
A Research Study Comparing How Well Different Doses of the Medicine NN0519-0130 Lower Blood Sugar in People With Type 2 Diabetes
Investigation of the Safety and Efficacy of Once Weekly NNC0519-0130 in Participants With Type 2 Diabetes - a Dose Finding Study

Study Focus

Diabetes Mellitus, Type 2

NNC0519-0130

Interventional

drug

Sponsor & Location

Novo Nordisk A/S

Chula Vista,Fresno,Fresno,La Mesa,Lancaster,Lomita,Los Alamitos,Montclair,Toluca Lake,Torrance,Tustin,Aurora,Clearwater,Miami,Columbus,Blackfoot,Peoria,Oxon Hill,Rockville,Springfield,Butte,Las Vegas,, Australia,Canada,India,Japan,South Africa,South Korea,United States of America

Timeline & Enrollment

Phase 2

Mar 18, 2024

Aug 26, 2025

288 participants

Primary Outcome

Change in Glycated haemoglobin (HbA1c)

Summary

This study will look at how well a new medicine called NNC0519-0130 helps people with type 2
 diabetes lower their blood sugar and body weight. The study will test up to 7 different doses
 of NNC0519-0130. Which treatment participant will get is decided by chance. Participants will
 take 1-3 injections once a week. The study medicine will be injected under skin with a thin
 needle in the stomach, thigh, or upper arm. The study will last for about 40 weeks.

ICD-10 Classifications

Type 2 diabetes mellitus
Type 2 diabetes mellitus with unspecified complications
Type 2 diabetes mellitus with other specified complications
Type 2 diabetes mellitus without complications
Type 2 diabetes mellitus with multiple complications

Data Source

ClinicalTrials.gov

NCT06326047

Non-Device Trial